{
    "organizations": [],
    "uuid": "26a6927b8f9dfd987602d976db902eeebc1e3bb0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-catabasis-pharmaceuticals-reports/brief-catabasis-pharmaceuticals-reports-q1-loss-per-share-0-29-idUSASC0A1FL",
    "ord_in_thread": 0,
    "title": "BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Catabasis Pharmaceuticals Inc:\n* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS\n* Q1 LOSS PER SHARE $0.29 * Q1 EARNINGS PER SHARE VIEW $-0.20 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, 2018, CATABASIS HAD CASH AND CASH EQUIVALENTS OF $17.0 MILLION\n* BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS THROUGH DECEMBER 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-10T20:08:00.000+03:00",
    "crawled": "2018-05-11T12:31:24.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "catabasis",
        "pharmaceutical",
        "inc",
        "catabasis",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "review",
        "business",
        "progress",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "march",
        "catabasis",
        "cash",
        "cash",
        "equivalent",
        "million",
        "belief",
        "sufficient",
        "cash",
        "fund",
        "operation",
        "december",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}